An observational study in Acute Lymphoblastic Leukemia. and Acute Myeloblastic Leukemia, sponsored by National Institute of Cancerología. Status unknown at 1 site in Mexico. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2013-11-15.
Sponsored by National Institute of Cancerología · Observational
Results of actual treatment in ALL are not optimal. New prognostic factors, which may determine clinical \& molecular response are required. Hyper-CVAD is an internationally accepted schema for such patients. The objective of this pilot study is to evaluate polymorphisms regarding RFC (reduced folate carrier) and MTHFR enzyme, which may affect the function of these proteins, and therefore the intracellular bioavailability of methotrexate. Also, the expression levels of hENT1 and dCK will be evaluated, since such genes codify for citarabine intracellular transport and activation, respectively. Clinical characteristics will be tabulated and analyzed for responders \& non-responders patients. Uni- \& multivariate analysis will be done to evaluate factors influencing on response and survival.
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's planned enrollment of 50 is below the median of 120 across 744 observational studies indexed under Leukemia.
Browse Leukemia studies →National Institute of Cancerología is the lead sponsor of 38 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with acute lymphoblastic leukemia
Exclusion Criteria:
Adult patients with ALL attending at the Instituto Nacional de Cancerologia Mexico.
To evaluate clinical response
To evaluate clinical response after ending Hyper-CVAD schema for ALL patients. To evaluate clinical response \& DFS in relation with hENT1 \& dCK expression levels in AML patients.
Time frame: December 2012
Clinical responses in relation with SNP's or gene expression
Time frame: clinical response.
This study is status unknown, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Cancerología